Nextbiomedical Co (XKRX:389650) Beneish M-Score: -2.04 (As of Aug. 27, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XKRX:389650 Nextbiomedical Co Ltd XKRX:389650
38 GF Score
Price ₩33,550.00
! 1 Warning Sign
View Full Analysis

What is Nextbiomedical Co Beneish M-Score?

Nextbiomedical Co XKRX:389650 +1.82% 38 Beneish M-Score is -2.04 as of Aug. 27, 2026. GuruFocus rates XKRX:389650 with a GF Score™ of 38/100. The stock has 1 warning sign investors should review. Among 832 Biotechnology companies, Nextbiomedical Co ranks worse than 62.14% on this metric.

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -2.04 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for Nextbiomedical Co's Beneish M-Score or its related term are showing as below:

XKRX:389650' s Beneish M-Score Range Over the Past 10 Years
Min: -2.04   Med: -1.36   Max: -0.54
Current: -2.04

During the past 6 years, the highest Beneish M-Score of Nextbiomedical Co was -0.54. The lowest was -2.04. And the median was -1.36.


Nextbiomedical Co Beneish M-Score Historical Data

* Premium members only.

The historical data trend for Nextbiomedical Co's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Nextbiomedical Co Beneish M-Score Chart

Nextbiomedical Co Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beneish M-Score
Get a 7-Day Free Trial 0.00 0.00 0.00 -1.15 -1.50

Nextbiomedical Co Quarterly Data
Dec20 Dec21 Dec22 Mar23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 -1.22 -1.50 -0.54 -2.04

XKRX:389650 vs VRTX, REGN, RVMD: Beneish M-Score Comparison

For the Biotechnology subindustry, Nextbiomedical Co's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Nextbiomedical Co Beneish M-Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Nextbiomedical Co's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Nextbiomedical Co's Beneish M-Score falls into.


XKRX:389650
38GF Score
Nextbiomedical Co Ltd XKRX:389650
Beneish M-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Nextbiomedical Co Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Nextbiomedical Co for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 1.2184+0.528 * 0.9264+0.404 * 0.5559+0.892 * 1.4625+0.115 * 0.9784
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 1.1014+4.679 * -0.009592-0.327 * 0.6671
=-2.04

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Jun26) TTM:Last Year (Jun25) TTM:
Total Receivables was ₩4,308 Mil.
Revenue was 4935.531 + 4121.403 + 3799.083 + 4932.948 = ₩17,789 Mil.
Gross Profit was 3515.276 + 2773.523 + 2675.072 + 3575.075 = ₩12,539 Mil.
Total Current Assets was ₩44,236 Mil.
Total Assets was ₩63,579 Mil.
Property, Plant and Equipment(Net PPE) was ₩13,882 Mil.
Depreciation, Depletion and Amortization(DDA) was ₩534 Mil.
Selling, General, & Admin. Expense(SGA) was ₩1,940 Mil.
Total Current Liabilities was ₩8,819 Mil.
Long-Term Debt & Capital Lease Obligation was ₩693 Mil.
Net Income was -633.069 + -145.932 + -49.792 + 1061.353 = ₩233 Mil.
Non Operating Income was 0 + 0 + 0 + 0 = ₩0 Mil.
Cash Flow from Operations was 214.591 + -694.331 + 1331.354 + -9.181 = ₩842 Mil.
Total Receivables was ₩2,418 Mil.
Revenue was 3971.197 + 3773.575 + 2226.923 + 2191.781 = ₩12,163 Mil.
Gross Profit was 2830.639 + 2447.53 + 1315.248 + 1348.874 = ₩7,942 Mil.
Total Current Assets was ₩36,871 Mil.
Total Assets was ₩59,396 Mil.
Property, Plant and Equipment(Net PPE) was ₩13,349 Mil.
Depreciation, Depletion and Amortization(DDA) was ₩502 Mil.
Selling, General, & Admin. Expense(SGA) was ₩1,204 Mil.
Total Current Liabilities was ₩12,005 Mil.
Long-Term Debt & Capital Lease Obligation was ₩1,316 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(4307.717 / 17788.965) / (2417.529 / 12163.476)
=0.242157 / 0.198753
=1.2184

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(7942.291 / 12163.476) / (12538.946 / 17788.965)
=0.652962 / 0.704872
=0.9264

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (44236.368 + 13882.475) / 63578.724) / (1 - (36871.119 + 13348.842) / 59396.078)
=0.085876 / 0.15449
=0.5559

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=17788.965 / 12163.476
=1.4625

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(501.617 / (501.617 + 13348.842)) / (533.61 / (533.61 + 13882.475))
=0.036217 / 0.037015
=0.9784

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(1940.17 / 17788.965) / (1204.467 / 12163.476)
=0.109066 / 0.099023
=1.1014

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((692.905 + 8818.72) / 63578.724) / ((1315.879 + 12004.634) / 59396.078)
=0.149604 / 0.224266
=0.6671

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(232.56 - 0 - 842.433) / 63578.724
=-0.009592

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Nextbiomedical Co has a M-score of -2.04 suggests that the company is unlikely to be a manipulator.

Frequently Asked Questions Learn more about Beneish M-Score →
What does a Beneish M-Score of -2.04 mean?
Nextbiomedical Co (XKRX:389650) has a Beneish M-Score of -2.04 as of Aug. 27, 2026. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Nextbiomedical Co and its competitors. According to the industry distribution chart, Nextbiomedical Co ranks #517 out of 832 companies in the Biotechnology industry, placing it in the top 62.1%.
Is Nextbiomedical Co's Beneish M-Score too high?
Nextbiomedical Co's current Beneish M-Score is -2.04. Based on the distribution chart, Nextbiomedical Co ranks #517 out of 832 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Nextbiomedical Co has a GF Score™ of 38/100, reflecting its overall financial health beyond just this single metric.
How does Nextbiomedical Co's Beneish M-Score compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Nextbiomedical Co ranks #517 out of 832 companies for Beneish M-Score. This places Nextbiomedical Co in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beneish M-Score for a Biotechnology company?
A good Beneish M-Score depends on the Biotechnology industry context. However, Beneish M-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beneish M-Score mean?
A high Beneish M-Score can signal that a stock is expensive relative to its fundamentals. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Nextbiomedical Co and its competitors. Nextbiomedical Co's current Beneish M-Score is -2.04. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nextbiomedical Co stock overvalued right now?
Nextbiomedical Co (XKRX:389650) has a current Beneish M-Score of -2.04. The current Beneish M-Score is -2.04. Nextbiomedical Co's overall GF Score™ is 38/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beneish M-Score calculated?
Beneish M-Score is calculated from a company's financial statements. For Nextbiomedical Co (XKRX:389650), the current Beneish M-Score is -2.04 as of Aug. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Nextbiomedical Co Business Description

Address Venture-ro, No. 6, 100 beongil, Yeonsu-gu, Incheon, KOR
Nextbiomedical Co Ltd is an bio-solution company. The company develops and commercializes therapeutic agents for treating diseases based on polymer and drug delivery system technology. The company has developed products that include endoscopic hemostatic agents, vascular embolic microspheres, and others.
38GF Score

Get the complete analysis for XKRX:389650

Beneish M-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₩33,550.00
Price